Risk Factors for Valvulopathy Among Childhood Cancer Survivors
(2025) In JAMA Oncology 11(12). p.1449-1457- Abstract
Importance Substantial improvements in childhood cancer survival have created a critical need to address serious long-term health complications, such as valvular heart disease (VHD). Objective To identify treatment-related risk factors for VHD in a large European cohort of long-term childhood cancer survivors. Design, Setting, and Participants This nested case-control study used data from the PanCareSurFup (PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies) and ProCardio cohorts, including detailed radiation dose reconstruction and chemotherapy exposure, for childhood cancer survivors from 7 European countries, diagnosed between 1940 and 2009, who survived at least 5 years after cancer diagnosis. Case patients,... (More)
Importance Substantial improvements in childhood cancer survival have created a critical need to address serious long-term health complications, such as valvular heart disease (VHD). Objective To identify treatment-related risk factors for VHD in a large European cohort of long-term childhood cancer survivors. Design, Setting, and Participants This nested case-control study used data from the PanCareSurFup (PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies) and ProCardio cohorts, including detailed radiation dose reconstruction and chemotherapy exposure, for childhood cancer survivors from 7 European countries, diagnosed between 1940 and 2009, who survived at least 5 years after cancer diagnosis. Case patients, defined as having symptomatic VHD, were matched with controls 1:2 by subcohort, sex, age at cancer diagnosis, and calendar year of initial diagnosis. Data were analyzed from October 2023 to June 2025. Exposures Doses were calculated by performing a whole-body dosimetric reconstruction using a voxel-based anthropomorphic phantom with more than 200 delineated anatomic structures or substructures. Cumulative dose to cytotoxic agents was also assessed. Main Outcome and Measure Development of symptomatic VHD (grade ≥3 per the Common Terminology and Criteria for Adverse Events, version 4.03). Results Of the 225 cases, 136 participants (60.4%) were male, and 195 (86.7%) were diagnosed with VHD beyond 20 years from childhood cancer. Survivors receiving a mean heart radiation therapy (RT) dose of 5 to less than 15 Gy had an increased risk of VHD (odds ratio [OR], 4.7; 95% CI, 2.1-10.7) compared to those without heart RT, with higher risk when more than half of the heart was exposed. The heart RT dose response appeared exponential, with the OR being 104.1 (95% CI, 27.8-389.6) for mean heart dose of 30 Gy or more, increasing considerably with follow-up from 6.0 (95% CI, 1.4-26.5) after 5 to 19 years to 71.4 (95% CI, 20.4-250.0) after 30 or more years. Cumulative anthracycline doses of 400 mg/m2 or higher were also associated with increased VHD risk (OR, 3.8; 95% CI, 1.4-10.3), showing an exponential dose-response pattern. Cumulative exposure to platinum agents was associated with VHD risk in a linear manner. No statistically significant associations were found for other chemotherapy agents or radiation to the spleen. Conclusion and Relevance In this case-control study, heart RT, anthracyclines, and platinum agents were associated with increased VHD risk in childhood cancer survivors. Risks from both RT and anthracyclines were amplified with age and follow-up, underscoring the need for long-term cardiac surveillance.
(Less)
- author
- organization
- publishing date
- 2025-12
- type
- Contribution to journal
- publication status
- published
- subject
- in
- JAMA Oncology
- volume
- 11
- issue
- 12
- pages
- 9 pages
- publisher
- American Medical Association
- external identifiers
-
- scopus:105022141162
- pmid:41066131
- ISSN
- 2374-2437
- DOI
- 10.1001/jamaoncol.2025.3863
- language
- English
- LU publication?
- yes
- id
- a6ed5113-be39-4ee5-bccd-367111c8ae40
- date added to LUP
- 2026-02-09 15:45:58
- date last changed
- 2026-06-30 09:08:57
@article{a6ed5113-be39-4ee5-bccd-367111c8ae40,
abstract = {{<p>Importance Substantial improvements in childhood cancer survival have created a critical need to address serious long-term health complications, such as valvular heart disease (VHD). Objective To identify treatment-related risk factors for VHD in a large European cohort of long-term childhood cancer survivors. Design, Setting, and Participants This nested case-control study used data from the PanCareSurFup (PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies) and ProCardio cohorts, including detailed radiation dose reconstruction and chemotherapy exposure, for childhood cancer survivors from 7 European countries, diagnosed between 1940 and 2009, who survived at least 5 years after cancer diagnosis. Case patients, defined as having symptomatic VHD, were matched with controls 1:2 by subcohort, sex, age at cancer diagnosis, and calendar year of initial diagnosis. Data were analyzed from October 2023 to June 2025. Exposures Doses were calculated by performing a whole-body dosimetric reconstruction using a voxel-based anthropomorphic phantom with more than 200 delineated anatomic structures or substructures. Cumulative dose to cytotoxic agents was also assessed. Main Outcome and Measure Development of symptomatic VHD (grade ≥3 per the Common Terminology and Criteria for Adverse Events, version 4.03). Results Of the 225 cases, 136 participants (60.4%) were male, and 195 (86.7%) were diagnosed with VHD beyond 20 years from childhood cancer. Survivors receiving a mean heart radiation therapy (RT) dose of 5 to less than 15 Gy had an increased risk of VHD (odds ratio [OR], 4.7; 95% CI, 2.1-10.7) compared to those without heart RT, with higher risk when more than half of the heart was exposed. The heart RT dose response appeared exponential, with the OR being 104.1 (95% CI, 27.8-389.6) for mean heart dose of 30 Gy or more, increasing considerably with follow-up from 6.0 (95% CI, 1.4-26.5) after 5 to 19 years to 71.4 (95% CI, 20.4-250.0) after 30 or more years. Cumulative anthracycline doses of 400 mg/m<sup>2</sup> or higher were also associated with increased VHD risk (OR, 3.8; 95% CI, 1.4-10.3), showing an exponential dose-response pattern. Cumulative exposure to platinum agents was associated with VHD risk in a linear manner. No statistically significant associations were found for other chemotherapy agents or radiation to the spleen. Conclusion and Relevance In this case-control study, heart RT, anthracyclines, and platinum agents were associated with increased VHD risk in childhood cancer survivors. Risks from both RT and anthracyclines were amplified with age and follow-up, underscoring the need for long-term cardiac surveillance.</p>}},
author = {{Aho Glele, Rivalin and Feijen, Elizabeth A.M. and Fresneau, Brice and Reulen, Raoul C. and Allodji, Rodrigue S. and Vu-Bezin, Giao and Schwartz, Boris and Journy, Neige and Minard-Colin, Véronique and Bagnasco, Francesca and Bardi, Edit and Belle, Fabiën N. and Byrne, Julianne and Van Dalen, Elvira C. and Teepen, Jop C. and Grabow, Desiree and Kaatsch, Peter and Hjorth, Lars and Jankovic, Momcilo and Kuehni, Claudia E. and Levitt, Gillian and Veres, Cristina and Aerts, Isabelle and Zadravec Zaletel, Lorna and Van der Pal, Helena J.H. and Ronckers, Cecile and Sacerdote, Carlotta and Skinner, Roderick and Jakab, Zsuzsanna and Michel, Gisela and Terenziani, Monica and Haddy, Nadia and Thierry-Chef, Isabelle and Cardis, Elisabeth and Diallo, Ibrahima and Winter, David L. and Kremer, Leontien C.M. and Hawkins, Mike M. and De Vathaire, Florent}},
issn = {{2374-2437}},
language = {{eng}},
number = {{12}},
pages = {{1449--1457}},
publisher = {{American Medical Association}},
series = {{JAMA Oncology}},
title = {{Risk Factors for Valvulopathy Among Childhood Cancer Survivors}},
url = {{http://dx.doi.org/10.1001/jamaoncol.2025.3863}},
doi = {{10.1001/jamaoncol.2025.3863}},
volume = {{11}},
year = {{2025}},
}